Spots Global Cancer Trial Database for Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
Official Title:
Study ID: NCT00051688
Conditions
Study Description
Brief Summary: The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ACRC/Arizona Clinical Research Center, Tucson, Arizona, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States
Cancer Institute Medical Group, Santa Monica, California, United States
Georgetown University Medical Center, Lombardi Cancer Center, Washington, District of Columbia, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Kansas City Oncology and Hematology Group, Kansas City, Missouri, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
